-
Product Name
Anti-PD-L1/B7-H1/CD274 antibody
- Documents
-
Description
Rabbit monoclonal to PD-L1/B7-H1/CD274
-
Tested applications
ELISA, IHC-P
-
Species reactivity
Human PD-L1 / B7-H1 / CD274
No cross-reactivity in ELISA with Human B7-1; Human B7-2; Mouse B7-H1; Non-blocking; This B7-H1/PD-L1 antibody can not block the binding of recombinant PD1 to its recombinant ligand B7-H1/PD-L1. -
Alternative names
B7-H antibody; B7H1 antibody; B7h1 antibody; CD274 antibody; Cd274 A530045L16Rik antibody; MGC142294 antibody; MGC142296 antibody; Pdcd1l1 antibody; PDCD1L1 antibody; Pdcd1lg1 antibody; PDCD1LG1 antibody; PDL1 antibody; Pdl1 antibody; PD-L1 antibody; PD-L1 antibody
- Immunogen
-
Isotype
Rabbit IgG
-
Preparation
This antibody was obtained from a rabbit immunized with purified, recombinant Human PD-L1 / B7-H1 / CD274 (rh PD-L1 / B7-H1 / CD274; NP_054862.1; Met 1-Thr 239).
-
Clonality
Monoclonal
-
Formulation
0.2 μm filtered solution in PBS with 5% trehalose
-
Storage instructions
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles. -
Applications
ELISA: 0.1-0.2 μg/mL
This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Human B7H1.
IHC-P: 5-15 μg/mL
-
Validations
PD-L1 / B7-H1 / CD274 Antibody, Rabbit MAb, Immunohistochemistry
Immunochemical staining of human B7H1 in human placenta with rabbit monoclonal antibody (5 µg/mL, formalin-fixed paraffin embedded sections). Positive staining was localized to trophoblast.
-
Background
Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain, and together with PD-L2, are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.
-
References
- Iwai Y, et al. (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 99(19): 12293-7.
- Ghebeh H, et al. (2006) The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 8(3): 190-8.
- Salih HR, et al. (2006) The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans. Exp Hematol. 34(7): 888-94.
- Wilcox RA, et al. (2009) B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood. 114(10): 2149-58.
- Ruggiero A, et al. (2009) Crystal structure of PD-L1, a ribosome inactivating protein from Phytolacca dioica L. leaves with the property to induce DNA cleavage. Biopolymers. 91(12): 1135-42.
Related Products / Services
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"